Abvc Biopharma (ABVC) Total Current Liabilities (2010 - 2026)

Abvc Biopharma (ABVC) has reported Total Current Liabilities for 14 consecutive years, with $5.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Current Liabilities fell 12.83% year-over-year to $5.7 million; the trailing twelve-month figure through Jun 2026 stood at $5.7 million (down 12.83% YoY), and the FY2025 full-year result was $6.2 million, down 6.0% from the prior year.
• Total Current Liabilities rose to $5.7 million in Q2 2026 per ABVC's latest filing, from $5.4 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $6.7 million in Q1 2025 and bottomed at $3.6 million in Q2 2022.
• Historically, Total Current Liabilities has averaged $5.6 million across 5 years, with a median of $5.9 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities retreated 21.49% in 2022, then surged 58.34% in 2023.
• Over 5 years, Total Current Liabilities stood at $5.5 million in 2022, then climbed by 10.07% to $6.1 million in 2023, then rose by 7.47% to $6.6 million in 2024, then declined by 6.0% to $6.2 million in 2025, then declined by 7.62% to $5.7 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $5.7 million, $5.4 million, and $6.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.